This module distills the most impactful clinical and technological advancements presented at the 86th American Diabetes Association Scientific Sessions. Participants will review the latest data on incretin-based therapies, including phase 3 trial results for triple receptor agonists like retatrutide, which have demonstrated superior weight loss and glycemic control. The course also covers critical updates in diabetes technology, such as the emergence of dual glucose-ketone sensors for early diabetic ketoacidosis (DKA) detection and expanded evidence for continuous glucose monitoring (CGM) in non-insulin-treated type 2 diabetes. Clinicians will gain actionable insights into how these innovations are streamlining daily management and improving time-in-range outcomes for diverse patient populations.